SUPARTZ Joint Fluid Therapy smith&nephew

Proven pain relief


SUPARTZ Joint Fluid Therapy is trusted

An extensive worldwide clinical history of 155 million injections gives doctors and patients confidence that SUPARTZ Joint Fluid Therapy will safely and effectively relieve knee pain in patients and get them back to their daily activities.

SUPARTZ Joint Fluid Therapy is effective

The safety and effectiveness of SUPARTZ Joint Fluid Therapy were studied in five randomized, prospective, double-blind, placebo-controlled, multicenter clinical trials involving 1,155 patients. These studies demonstrated a statistically significant greater reduction of total Lequesne scores (34%) in the SUPARTZ Joint Fluid Therapy-treated group than in the saline control group. The SUPARTZ Joint Fluid Therapy clinical history includes follow-up studies lasting six years.

SUPARTZ Joint Fluid Therapy is safe

An integrated analysis of five randomized, prospective, double-blind, placebo-controlled, multicenter studies found that adverse events occurred at similar rates in the patients treated with SUPARTZ Joint Fluid Therapy and those treated with saltwater. 1

For complete SUPARTZ product information, and before prescribing, please see the package insert

Download the Package Insert

Molecular weight and method of action

The molecular weight of SUPARTZ Joint Fluid Therapy is 620,000 - 1,170,000 Daltons. The American College of Rheumatology reports that the molecular weight of a hyaluronan product has no demonstrated connection to its clinical efficacy. The method of action remains unclear, although several options have been proposed - "inhibition of inflammatory mediators such as cytokines and prostaglandins, stimulation of cartilage matrix synthesis and inhibition of cartilage degradation, and a direct protective action on nociceptive nerve endings."2

1 - Ueno Y., et al. Investigation on result of use after launch of ARTZ and ARTZ Dispo. Evaluation on the efficacy, safety and utility in the medication for osteoarthritis of the knee and periarthritis of the shoulder. Jpn Pharmacol & Ther. 1995; 23(8):2151-2170. 2 - American College of Rheumatology, Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee, American College of Rheumatology Subcommittee on Osteoarthritis Guidelines, Volume 43, No. 9, September 2000, pp 1905-1915.